Ann: Investor Presentation - February 2019, page-2

This presentation seems clear that fda diagnostic aid as we all invested in is all but abandoned. The product that aims to assist gps but is not in any way diagnostic is unlikely be adopted by time poor doctors when it is merely a data source in the same way wearables provide. Medibio  are  not likely to commercialise at all which they’ve changed to CY end 19. Small pilots. No diagnostics. No de novo. No quality  and regulatory staff. No FDA experience. With the one product they have developed listed for a possible longer term focus but not next 12 months. No burn but no product.  

I think they just killed all further subscription likelihood. Goad Fidelity and Regal don’t manage my funds.